Patents Assigned to WUXI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
  • Publication number: 20210009966
    Abstract: Provided is a method for large-scale preparation of a purified preparation of a recombinant lentiviral vector at the GMP grade. The method comprises: (a) providing raw material feed liquid to be purified that comprises recombinant viral vectors; (b) carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors; (c) optionally concentrating the filtrate to obtain a concentrated filtrate; (d) purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product comprising the recombinant viral vectors; and (e) subjecting the crude pure product obtained in the previous step to liquid exchange and elaborate purification to obtain the purified recombinant viral vectors.
    Type: Application
    Filed: March 28, 2019
    Publication date: January 14, 2021
    Applicants: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD., WUXI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
    Inventors: Yi Hong, Ting Yan, Jiangguo Ying, Haojie Zhang, Li Zhang, Fei Wang, Dijun Zhao, Luyi Zhang